The clinical result is a medication that works through three complementary pathways simultaneously: Reduced appetite via GLP-1 and GIP receptor activation (eating less) Improved metabolic efficiency via GIP receptor activation on adipose tissue (storing fat less efficiently) Increased energy expenditure via glucagon receptor activation (burning more calories) This triple mechanism explains why retatrutides Phase 3 trial results exceed Mounjaros, which already uses two pathways
Research suggests glutathione supplementation may help improve insulin resistance, reduce cell damage in fatty liver disease, and increase mobility for people with peripheral artery disease
(More information) Prospective cohort studies indicate that higher vitamin C status, assessed by measuring circulating vitamin C, is associated with lower risks of hypertension, coronary heart disease, and stroke
Dupre, J., Ross, S
Patients across Miami, Fort Lauderdale, Boca Raton, Orlando, Tampa, and Jacksonville are increasingly turning to telehealth providers to navigate insurance approvals and start treatment faster
Eisai Presents New Data on the Continued and Expanding Benefit of Leqembi (lecanemabirmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025